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ABSTRACT
This systematic review and meta-analyses investigates the expression of the 
cell checkpoint regulator, mitotic arrest deficiency protein 2 (MAD2) in cancerous 
tissue and examines whether an association exists between MAD2 levels and cancer 
survival and recurrence. Studies investigating MAD2 expression in cancer tissue 
utilising immunohistochemistry (IHC) were identified by systematic literature searches 
of Medline, Embase and Web of Science databases by October 2015. Random effects 
meta-analyses were performed to generate pooled hazard ratios (HRs) with 95% 
confidence intervals (CIs) of overall and progression-free survival according to MAD2 
expression. Forty-three studies were included in the overall review. In 33 studies 
investigating MAD2 expression by IHC in cancer tissue, a wide range of expression 
positivity (11–100%) was reported. Higher MAD2 expression was not associated with 
an increased risk of all-cause mortality in a range of cancers (pooled HR 1.35, 95% CI 
0.97–1.87; P = 0.077, n = 15). However, when ovarian cancer studies were removed, 
a significant pooled HR of 1.59 for risk of all-cause mortality in other cancer patients 
with higher expressing MAD2 tumours was evident (95% CI, 1.17–2.17; P = 0.003,  
n = 12). In contrast, higher MAD2 expression was associated with significant decreased 
risk of all-cause mortality in ovarian cancer patients (pooled HR = 0.50, 95% CI, 
0.25–0.97; P = 0.04, n = 3). In conclusion, with the exception of ovarian cancer, 
increased MAD2 expression is associated with increased risk of all-cause mortality 
and recurrence in cancer. For ovarian cancer, reduced levels of MAD2 are associated 
with poorer outcome. Further studies are critical to assess the clinical utility of a MAD2 
IHC biomarker. 
INTRODUCTION
The mitotic arrest deficiency protein 2 (MAD2) is an 
essential spindle assembly checkpoint (SAC) monitoring 
accurate chromosomal alignment at the metaphase 
plate before mitosis [1]. Much evidence implicates the 
overexpression of MAD2 as a driver of chromosomal 
instability in many cancer types [2–5]. Tumour formation 
resulting from loss of one of the MAD2 alleles suggests 
haploinsufficiency at this locus which is common to other 
SAC proteins [6]. MAD2 also functions beyond the SAC 
where it is known to interact with a number of checkpoint-
unrelated proteins such as insulin receptor, estrogen 
receptor β and tumour necrosis factor α convertase [7–9]. 
Moreover, MAD2 influences cell proliferation, tumour 
metastasis and tumour recurrence [5]. 
MAD2 expression is regulated by a diverse range 
of cancer-associated proteins including the tumour 
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suppressor protein p53, breast cancer 1 (BRCA1), the 
c-MYC oncogene, the checkpoint with forkhead and 
ring finger domains, E3 ubiquitin protein ligase (CHFR), 
E2 factor (E2F) and numerous microRNAs [10–16] . 
Moreover, MAD2 is a ubiquitously expressed protein, 
expressed by most tissues of the body, found localised in 
the nuclear, perinuclear and cytoplasmic compartments 
[17–19]. It is reliably measured by real-time PCR, western 
blots or immunohistochemistry (IHC) methods [19, 20]. 
The majority of studies predominantly evaluate MAD2 
expression by IHC. 
The association between MAD2 IHC expression 
and survival has been examined in a diverse range of 
carcinomas including colorectal, bladder, testicular, 
breast and ovarian, where both overexpression and low 
levels of MAD2 expression have been associated with 
survival, depending on the tumour type [20, 21]. However, 
inconsistencies in terms of study design, staining site 
analysed, expression cut-offs and study quality have 
precluded the interpretations of these study results, and the 
evaluation of MAD2 as a potential prognostic biomarker 
of patient survival. Therefore, there is an unmet need 
to systematically review published data relating to the 
extent of MAD2 expression in various tissues and the 
relationship between MAD2 expression evaluated through 
IHC and cancer prognosis.
The primary aim of this novel review and meta-
analyses was to systematically identify research papers 
that analysed the association between MAD2 IHC staining 
and cancer patient survival and/or recurrence, and from 
these studies elucidate whether there is an association 
between MAD2 expression and cancer patient prognosis 
by conducting a meta-analysis.
 RESULTS
The literature search identified 881 citations for 
review (Medline n = 460, Embase minus Medline n = 22 
and Web of Science n = 399). As shown in Figure 1, after 
exclusion of publications following screening for title 
and abstract by reviewers, 81 papers remained and after 
removal of duplicates, 43 studies were fully screened and 
included in the review. 
MAD2 expression in cancerous tissue
A total of 33 studies provided expression analysis 
of MAD2 where expression of positivity ranged from 
11.1 to 100% in cancerous tissue. Difficulties arose in the 
comparison of studies due to the fact that the majority of 
cancer types only have one study. In cancer types where 
more than one study has been undertaken, comparisons 
between studies were extremely complicated. This was as 
a result of the different expression methods utilised and 
the expression reported as different measures of central 
tendency (Supplementary Table 1). 
Association with overall survival
As shown in Table 1, studies included in this meta-
analysis were published between 2008 and 2015, with 
nine studies originating from East Asia, three studies from 
Europe, one study from Brazil and one study from the 
USA. Cancer sample cohorts ranged from 27 to 400. The 
mean follow-up times, ranged from 3 to 3.29 years with 
median follow-up times ranging from 1.6 to 5.04 year. 
MAD2 IHC was mostly evaluated on tissue microarrays 
(TMAs), one study used both TMAs and full face sections, 
while six studies did not report the sample type assessed. 
Monoclonal antibodies were reported in eight studies, 
three studies reported the use of polyclonal antibodies 
and three studies did not report the type of antibody used. 
The cellular location investigated for MAD2 staining was 
nuclear in six studies, cytoplasmic for two studies, both 
nuclear and cytoplasmic in five studies and unreported 
in one study (Table 1). In the IHC staining analysis of 
MAD2 expression, four studies reported the involvement 
of a pathologist in the scoring of the IHC slides while 10 
studies did not state if a pathologist assisted in the scoring. 
Two assessors determined MAD2 IHC staining in six 
studies, a single pathologist assessed MAD2 IHC scoring 
in one study and the remaining seven studies did not state 
the number of assessors.
Sufficient data was provided by 14 studies, which 
contained 2318 patient samples to be included in the 
meta-analysis, to assess the association between MAD2 
expression and overall survival (Table 2). As shown in 
Figure 2, higher MAD2 expression was associated with 
a non-significant increased risk of all-cause mortality in 
a range of cancers (pooled HR 1.35, 95% CI 0.97–1.87; 
P = 0.08). This investigation had an I² value of 
72% (P < 0.001), highlighting the substantial heterogeneity 
between studies, which was not markedly reduced in 
sensitivity analyses excluding individual studies (Figure 2).
Interestingly, when all ovarian cancer studies are 
removed, as shown in Figure 2, a significant pooled HR 
of 1.59 for risk of all-cause mortality in patients with 
high expressing MAD2 tumours was evident compared to 
those with low expressing MAD2 tumours (95% CI, 1.17–
2.17; P = 0.003), but still incurred high heterogeneity 
(I² = 65%, P = 0.001). When only ovarian studies were 
investigated as a separate entity, higher MAD2 expression 
was associated with a significantly decreased risk of all-
cause mortality compared to those with low expressing 
MAD2 tumours (pooled HR 0.50, 95% CI, 0.25–0.97; 
P = 0.04). This meta-analysis had an I2 value of 27% 
(P = 0.25) indicating that the results of the studies are 
reliably consistent with mild heterogeneity (Figure 2). 
There was no evidence of publication bias in the funnel 
plot assessing overall survival for studies (P = 0.82, 
Supplementary Figure 1). However from undertaking the 
meta-analysis it is evident that the different ovarian cancer 
subtypes may respond differently to MAD2 expression 
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Table 1: Characteristics of studies assessing the expression of MAD2 immunohistochemistry in 
cancer
Author Year Cancer site(s) Samples assessed
Age range, 
years (mean or 
median)
Sex
Number 
of normal 
tissue 
samples
Number of
 cancer 
samples
Site of staining Expression analysis
Survival 
analysis
Agosten 2007 Breast TMA NR Females NR 85 
Perinuclear/
cytoplasmic
 X
Burum-Auensen 2008 Colorectal TMA 35–88 (68)
Males & 
females
17 55 Nuclear  
Burum-Auensen 2007
Colorectal 
(UC-related)
TMA NR NR 10 8 
Nuclear/
additional staining 
was cytoplasmic
 X
Burum-Auensen 2010 Testicular TMA NR Males 21 336 
Nuclear with 
weak staining of 
cytoplasm 
 X
Choi 2013 Bladder TMA 23–97 (68) 
Males & 
females
NR 339
Nuclear & 
cytoplasmic
 
Du 2011 Breast NR 33–83 (54) Females NR 117 
Nuclear/
sometimes 
cytoplasmic 
 X
Fung 2007 Testicular NR 24–67 (37.7) Males 12 23 
Nuclear & 
cytoplasmic
 X
Furlong 2012 Ovarian  
TMA and full 
face 
NR Females NR 82 Nuclear  
Genga 2015
Myelodysplastic 
syndrome 
NR 18–91 (59.5)
Males & 
females
10 40 Cytoplasmic  
Gladhaug 2010 Pancreatic TMA NR
Males & 
females
NR 218 Nuclear  
Hannisdal 2010 Tonsillar TMA
43 aged < 60 
57 aged ≥ 60 
Males & 
females
NR 105 
Nuclear & 
cytoplasmic
 
Hisaoka 2008 Sarcoma NR NR NR 50 50 Nuclear  X
Kato 2012 Lung TMA 123 aged < 60 
239 aged ≥ 60 
Males & 
females
NR 362 NR  X
Kato 2011 Lung TMA 26–87 (63.5) Males & 
females
NR 358 Nucleoplasmic  
Kim 2014 Uterine cervical TMA 22–82 (44.1) Females 100 232 Nuclear & 
cytoplasmic
 
Ko 2010 Salivary duct NR 42–82 (58.5) Males & 
females
NR 27 Cytoplasmic  
Li 2013 Endometrial NR 35–85 (51) Females
30 normal, 
30 
hyperplasia
63 
Nuclear & 
cytoplasmic
 
Li 2003 Colorectal NR 28–81 (54.8) Males & 
females
38 38
Brown-yellow 
staining mainly in 
cell plasma
 X
Li 2004 Colorectal NR 25–79 (52.5) Males & 
females
40 40 
Brown-yellow 
staining mainly in 
cell plasma
 
Liao 2013 Cervical NR 23–65 (43.5) Females 10 90 Nuclear & 
cytoplasmic
 X
McGrogan 2014 Ovarian TMA 32–77 (52) Females NA 72 Nuclear  
Morishta 2012 Uterine cervical NR 22–69 Females NA 53 Nuclear  X
Nakano 2012 Ovarian serous NR 26–82 Females NA 41 Nuclear  
Nakano 2012
Ovarian 
mucinous
NR 13–88 Females 30 98 Nuclear  
Park 2013 Ovarian NR
59 aged < 60 
26 aged ≥ 60
Females NA 85 
Nuclear 7 
cytoplasmic
 
Rizzardi 2014 Oral SCC NR 44–86 (61)
Males & 
females
NA 49 Nuclear  
Sotillo 2006 Various TMA NR NR NA 351 Nuclear  X
Suraokar 2014 Mesothelioma TMA NR NR NA 80 
Nuclear & 
cytoplasmic
 
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levels. Low MAD2 levels correlated with poorer survival 
as evident in Figure 2. In mucinous ovarian cancers, a 
different outcome was obtained where low MAD2 levels 
correlate with decreased risk of all-cause death. However, 
the association between MAD2 levels and survival in 
mucinous cancers may not be valid as the HR is extremely 
close to 1 (HR = 1.11, 95% CI; 0.25–4.90) arising from a 
single study.
Association with progression-free survival
The meta-analyses of progression-free survival 
included studies published between 2010 and 2014 with 
five studies from East Asia and two studies from Europe 
(Table 1). Cancer sample cohorts ranged from 27 to 358. 
The mean/median follow-up times reported ranged from 
2–5 years. 
The use of TMAs or full face sections for MAD2 
IHC analysis was unreported in three studies.  However, 
most other studies utilised TMAs with one study using 
both TMAs and full face sections. Monoclonal antibodies 
were reported in five studies with two studies not reporting 
the type used. MAD2 nuclear staining was reported in 
three studies, MAD2 cytoplasmic staining was reported 
in one study and both MAD2 nuclear and cytoplasmic 
staining assessed in two studies (Table 1). MAD2 IHC 
Teixeira 2015 Oral cancer NR
25 aged < 62, 
29 aged ≥ 62 
Males & 
females
NA 54
Nuclear & 
cytoplasmic
 
Thoma 2009 Renal TMA NR NR NA > 200 Nuclear  X
Uemura 2009 Esophageal TMA 32 aged < 60, 
28 aged ≥ 60
Males & 
females
60 60
Nuclear & 
cytoplasmic
 X
Wang 2009 Gastric TMA NR Males & 
females
102 102 
Nuclear & 
cytoplasmic
 
Yu 2010 Osteosarcoma NR 12–54 (25.2) Males & 
females
20 48 
Nuclear & 
cytoplasmic
 
Zhang 2008 Hepatocellular TMA
184 <median 
age, 216> 
median age
Males & 
females
NR 400 Nuclear X 
Zhao 2014 Endometrial NR NR (50.8) Females 30 63 Nuclear & 
cytoplasmic
 X
NA = not applicable, NR = not reported, TMA = tissue microarray, UC = Ulcerative Colitis.
Figure 1: Flowchart of study selection that assessed MAD2 immunohistochemistry in cancer. Three databases (Medline, 
Embase and Web of Science) were utilised to identify potential papers for inclusion in meta-analysis. After removal of duplicates and 
studies not fulfilling inclusion criteria, data was extracted from these full text papers to be included in meta-analyses evaluating MAD2 
percentage expression and both progression-free and overall survival in relation to MAD2 expression.
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Table 2: Descriptive characteristics and results of studies investigating MAD2 expression and 
cancer progression
Author Cancer site(s) Comparison 
(definition)*
Total number 
of patients/
deaths
 Mean (max.) 
follow-up, yrs 
Relative risk 
(95% CI) 
Overall/cancer-
specific survival
Relative risk 
(95% CI) 
Recurrence/
disease free 
survival
Adjustments
Burum-
Auensen 
Colorectal High v. low (≥ v. < 
median %)
55/NR NR HR 0.83, 95%CI 
0.41–1.66, 
P = 0.59
Multivariate- 
variables NR
Choi Bladder High v. low (>3% v. 
≤ 3%, determined by 
receiver operating 
characteristic curves)
339/29 Mean NR, 
median was 
given = 3.08 
(15.25)
HR 2.68, 95% 
CI 1.29–5.55, 
P = 0.008
Unadjusted
Furlong Ovarian  High v. low (intensity 
3–4 v. 1–2)
82/NR NR HR 0.54, 95% 
CI 0.30–0.98, 
P = 0.041
HR 0.43, 95% 
CI 0.24–0.76, 
P = 0.004
Stage and 
grade
Genga Myelodysplastic 
syndrome 
High v. low (≥ 50% v. 
zero/< 50%) 
40/10 3.24 ± 1.7 
(5.75)
HR 15.79, 95% 
CI 2.42–102.86, 
P = 0.004
Age, gender, 
International 
Prognostic 
Scoring 
System at 
diagnosis
Gladhaug Pancreatobiliary High v. low (positive 
v. negative)
145/124 Mean NR, 
median was 
given = 1.6 (5)
Unadjusted
Pancreas - Intestinal High v. low (positive 
v. negative)
73/35 Mean NR, 
median was 
given = 1.6 (5)
HR 1.11, 95% CI 
0.51–2.43, P = 
0.786
Unadjusted
Kato Lung High v low (≥ 4 v. ≤ 3) 358/NR Mean NR, 
median given = 
5.04 (13.82)
HR 1.78, 95% 
CI 1.17–2.71, 
P = 0.008
HR 1.78, 95% 
CI 1.17–2.71, 
P = 0.008
Age, sex, pT 
status, pN 
status, pleural 
invasion, 
histological 
type, smoking 
history
Kim Uterine cervical High v. low (≥ 25% v. 
< 25%)
232/NR Mean NR, 
median was 
given = 2.75 
(10.25)
HR 0.83, 95% 
CI 0.31–2.23, 
P = 0.711
Unadjusted
Ko Salivary duct High v. low (intensity 
3–4 v. 1–2)
27/14 3.11 (9.75) HR 0.76, 95% 
CI 0.28–2.08  
P = 0.59
HR 0.84, 95% 
CI 0.28–2.51, 
P = 0.75
Unadjusted
Li Endometrial High v. low (positive 
v. negative)
63/7 3 (5.75) OR 17.4, 95% 
CI 3.5–87.62, 
P = 0.041
Unadjusted
McGrogan Ovarian High vs. low (intensity 
3–4 v. 1–2)
71/44 NR HR 0.51, 95% 
CI 0.23–1.10, 
P = 0.09
Tumour 
stage, grade, 
and optimal 
debulking
Nakano Ovarian serous High v. low (mean 
weighted scores 8–12 
v. 0–6)
41/20 NR HR 0.23, 95% 
CI 0.07–0.78, 
P = 0.019
HR 0.40, 95% 
CI 0.15–1.08, 
P = 0.069
Unadjusted
Nakano Ovarian mucinous High v. low (mean 
weighted scores 8–12 
v. 2–6)
128/NR NR HR 1.10, 95% 
CI 0.25–4.90, 
P = 0.903
Unadjusted
Park Ovarian High v. low (score ≥ 2 
v. ≤ 1)
85/NR 2 (6.58) HR 0.26, 95% 
CI 0.06–1.09, 
P = 0.07   
Age, stage, 
ovarian cancer 
type, p53 
expression
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staining analysis was assessed by a pathologist in two 
studies, while five studies did not state if a pathologist 
assisted in the scoring. MAD2 IHC staining was 
determined by at least two assessors in four studies and 
three studies did not state the number of assessors.
The meta-analysis of the association between MAD2 
expression and progression-free survival was assessed from 
seven studies containing 997 patient samples (Table 2). 
The results from all studies indicated that lower MAD2 
expression was not significantly associated with an 
increased risk of cancer recurrence (pooled HR = 0.65, 
95% CI, 0.36–1.19; P = 0.16, Figure 3). Similar to the 
association with overall survival, MAD2 expression is 
different in ovarian cancer compared to other cancers. A 
pooled HR for progression-free survival in patients with 
high-expressing non-ovarian MAD2 tumours compared 
to those with low expressing MAD2 tumours was 1.29 
(95% CI, 0.74–2.25; P = 0.38). Mild heterogeneity 
was observed (I2 value = 36%, P = 0.21). In contrast, a 
significant pooled HR of 0.43 (95% CI,0.29–0.65; P < 
0.001) was evident for progression-free survival in patients 
with high expressing MAD2 ovarian tumours compared to 
those with low expressing MAD2 tumours. An I2 value of 
0% was seen thereby identifying the results as consistent 
(P = 0.85). Moreover, the funnel plots for these analyses 
had minimal asymmetry, indicating no publication bias 
(P = 0.09, Supplementary Figure 1).
 DISCUSSION 
The aim of this novel systematic review with meta-
analyses was to summarise the extent of MAD2 expression 
in various tissues, and to investigate the association 
between MAD2 IHC expression and both overall and 
progression-free survival in a diverse range of cancers. 
The results highlight that higher MAD2 expression is 
Suraokar Mesothelioma High v. low (median,  
≥ v. < 44)
77/75 NR HR 1.60, 95% 
CI 1.02–2.51, 
P = 0.09
Unadjusted 
Yu Osteosarcoma High v. low (strong v. 
weak)
48/NR NR (9) HR 4.79, 95% 
CI 1.45–15.80, 
P < 0.01 
Unadjusted
Zhang Hepatocellular High v. low ( ≥10 v. 
< 10%)
400/302 3.29 (7) HR 1.44, 95% 
CI 1.16-1.80, 
P < 0.001
Unadjusted
CI = Confidence intervals, HR = Hazard ratio, NR = not reported, OR: Odds ratio.
Figure 2: Meta-analysis of highest v. lowest category of MAD2 protein levels and risk to overall cancer survival.
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associated with poorer survival in cancer patients, with 
the exception of ovarian cancer, where conversely, higher 
MAD2 expression is associated with improved survival. 
Our results indicated that MAD2 dysregulation is 
heavily tissue dependent in cancerous tissue with MAD2 
IHC levels ranging from 11.1% to 100% in cancerous 
tissue. Dysregulation of MAD2 levels by either up- or 
down-regulation of the gene can result in similar genomic 
aberrations and contribute to poorer patient survival 
[14, 40]. From our results, it is evident that high MAD2 
levels are associated with increased risk of all-cause death 
and cancer recurrence in non-ovarian cancers while low 
MAD2 levels are associate with poorer patient survival 
in ovarian cancer. Through in vitro and in vivo studies, 
high MAD2 levels are known to correlate with increased 
cellular proliferation, cellular transformation, migration, 
invasiveness and cancer metastasis which could contribute 
to this poorer patient outcome [41–44]. In addition, a 
number of studies have shown that low MAD2 levels 
correlate with resistance to commonly utilised anticancer 
agents such as taxol, DNA-damaging agents, vincristine 
and γ- irradiation. Therefore, it is not surprising that both 
low or high MAD2 levels can lead to a worsen patient 
prognosis [20, 45–48]. We previously reported that low 
MAD2 levels correlated with shorter progression-free 
survival in high grade serous ovarian cancer patients 
treated with platinum alone or in combination with 
paclitaxel and concluded this occurred as a result of 
increased resistance to paclitaxel [20]. 
In ovarian cancer, the association of high MAD2 
expression and survival is in contrast to the reported 
association of low MAD2 expression in the other cancer 
types included in this study and raises many questions 
about why MAD2 levels in ovarian cancer produce such 
a different response to patient survival. Currently, there is 
no explanation for this outcome. However, one possible 
explanation could be linked to the fact that unlike most 
cancer types that metastasise mainly via haematogenous 
or lymphatic routes, ovarian cancer, especially the most 
common and lethal type high grade serous carcinoma, 
metastasises through peritoneal dissemination [49]. 
Therefore as ovarian cancers progress and metastasise, 
they may possibly become less reliant on MAD2 
expression as previously reported in osteosarcoma [33]. 
Another possibility for the dysregulation of MAD2 
expression could be related to the regulation of MAD2 by 
BRCA1 [11]. BRCA1, which is mutated in 10% of ovarian 
cancers, is a transcriptional regulator of MAD2 and the 
aberrant activity of mutant BRCA1 in ovarian cancer 
may lead to altered transcriptional regulation of MAD2 
expression [11, 50]. Furthermore, ovarian tumours with 
high MAD2 levels were previously shown to be associated 
with increased sensitivity to taxol and improved patient 
survival, which may indicate that taxol response in ovarian 
tumours is possibly more dependent on the SAC activity 
of MAD2 than other cancer types [20, 51]. 
From the meta-analysis, the different subtypes of 
ovarian cancer have distinctive survival responses in terms 
of MAD2 expression. Studies of high grade serous ovarian 
cancer have shown that low MAD2 levels lead to poorer 
patient survival. In contrast, mucinous ovarian cancer 
appears to have a weaker inverse association between 
MAD2 levels and survival. A possible reasoning for this 
is that p53 and BRCA1, known regulators of MAD2, are 
commonly mutated in high serous ovarian cancer (Tp53 
mutation is ubiquitous in ovarian high grade serous 
carcinoma) and mutations in these genes are uncommon 
in other ovarian cancer subtypes such as mucinous, clear 
cell, endometrioid and low grade serous [11, 52]. Similarly 
in breast cancer, where p53 and BRCA1 are also regularly 
mutated, high MAD2 levels are associated with improved 
breast cancer specific survival [53]. Additionally, high 
Figure 3: Meta-analysis of highest v. lowest category of MAD2 protein levels and risk to progression free cancer 
survival.
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grade serous ovarian cancers express lower levels of 
E-cadherin and higher levels of N-cadherin compared 
to mucinous which is suggestive of a more epithelial-
mesenchymal transition phenotype which in-turn triggers 
tumour metastasis and possibly reduce the requirement of 
MAD2 for tumour spread [54, 55]. However, due to the 
limited number of studies on MAD2 expression in ovarian 
cancer, we cannot conclude if different ovarian subtypes 
have different survival rates depending on MAD2 
expression. Further analysis of MAD2 IHC expression in 
ovarian cancer may result in an IHC biomarker capable of 
stratifying the various ovarian cancers subtypes.
The heterogeneity in the meta-analysis of the 
correlation of MAD2 expression and overall survival in 
non-ovarian cancer studies was considerable between 
studies (64.8%). This could be attributable to the 
methodological diversity between studies, including 
sub-cellular location evaluated, scoring method utilised, 
expression threshold chosen and cancer site investigated. 
However, heterogeneity associated with meta-analyses of 
MAD2 expression and ovarian cancer prognosis was low.
The primary strength of this review lies in its 
ability to determine the effect of MAD2 expression on 
cancer survival for the first time, taken from a robust 
search of three databases for relevant studies. We were 
also able to standardise comparator groups, displaying 
all results as high v. low MAD2 levels, which overcomes 
potential confusion when comparing results from studies 
reporting high v. low or low v. high comparisons of 
MAD2 expression in relation to progression. The utility 
of prognostic markers are relevant to both understanding 
the mechanisms of progression and the ability to predict 
patient outcome (who may benefit from more/less intensive 
treatments or follow-up regimens). MAD2 could also 
be combined with other cell cycle proteins such as P27, 
CDC20, BUBR1.  However, there is limited evidence to 
suggest it would improve the prognostic ability of MAD2 
[21, 32, 41, 56, 57]. Furthermore, there was no evidence of 
publication bias associated with the meta-analyses reported 
in this study which increases the robustness of the results. 
One of the limitations of this review is that currently 
there is no standardised method for MAD2 IHC evaluation. 
Standardisation is vital across the entire IHC process from 
pre- to post-analytical stages and across laboratories to 
allow comparison between studies [58, 59]. This was 
particularly noticeable in the evaluation scoring system, 
where in some cases only MAD2 expression positivity 
was determined with the degree or percentage of MAD2 
staining intensity not considered. Furthermore, the 
arbitrary cut-off chosen to indicate high MAD2 expression 
differs from study to study. Between-study variances 
may also have resulted from diverse populations utilised 
in these studies especially since a number of the studies 
were quite small. Standardisation of these factors across 
studies will allow more comparable studies and provide 
more robust results. Another limitation is that a meta-
analysis for cancer-specific survival according to MAD2 
expression was unable to be undertaken due to a lack of 
studies reporting on this outcome. Also the majority of 
the studies utilised in this review were unadjusted for 
confounders known to affect survival of cancer patients 
such as age and stage [60, 61]. It is therefore difficult to 
determine how age and stage would affect the association 
of MAD2 expression on patient survival [62–64]. Of note, 
in the study that adjusted for age and stage the authors 
demonstrated that the association of MAD2 expression and 
survival was independent of these two confounders [25]. 
Therefore, future studies to analyse MAD2 IHC expression 
and survival should adjust for known cofounders to 
improve the reliability of results. Furthermore, as the 
studies examining MAD2 expression by IHC have utilised 
different sample numbers, power analysis should be 
considered before the study is undertaken to ensure that the 
data correctly identifies a statistical significant difference 
[65, 66]. Tissue microarrays may make a greater number 
of samples more achievable [67]. Despite these limitations, 
the overall outcomes remained consistent.
Recommendations for future studies evaluating the 
association of MAD2 IHC expression include standardising 
the reporting of results investigating high vs. low MAD2 
expression (the cut-offs may differ between different 
tumour types), and include required statistical values in 
order to undertake a meta-analysis such as HR and 95% 
CI. Additional studies should adjust for known clinical 
prognostic factors such as age and stage and also carry 
out power analysis. In this review, apart from ovarian 
cancer, there has only been one study in each cancer type 
that has met the required statistical findings in order to be 
included in a meta-analysis (Table 2). Thus, more studies 
in each cancer type are required to definitively determine 
if the correlation of MAD2 IHC expression with patient 
survival is cancer-specific. Furthermore, investigation of 
the molecular pathways involving MAD2 is essential to 
help researchers understand the mechanism behind the 
results of this review. Recent studies have also highlighted 
a potential therapeutic role for MAD2 where silencing of 
the MAD2 gene using siRNA lead to increased apoptotic 
cell death in a non-small cell lung cancer model [68]. 
Additionally, MAD2’s role as a predictive biomarker could 
also be particularly important. Further studies of cancer 
samples from patients treated with and without taxol/DNA- 
damaging agents would evaluate if MAD2 expression could 
predict the efficacy of these treatments on patient survival.
In conclusion, this review illustrates the potential 
for MAD2 IHC as a prognostic biomarker in cancer, 
especially in ovarian cancer where there is approximately 
a 50% lower risk of death or tumour recurrence in patients 
in the higher MAD2 expression category compared to 
the lower. An opposing prognostic role for increased 
risk of death in other cancer sites displaying high MAD2 
expression may exist. Further studies are critical to assess 
the clinical utility of a MAD2 IHC biomarker and the 
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molecular pathways affected by MAD2 that may improve 
patient outcomes. We outline recommendations for the 
standardised conduct and reporting of MAD2 expression 
studies in relation to cancer progression outcomes.
MATERIALS AND METHODS
This systematic review and meta-analysis adhered to 
the guidelines provided by the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [22]. 
Search strategy 
Systematic literature searches were performed 
using three electronic databases; Medline (US National 
Library of Medicine, National Institutes of Health, 
Bethesda, Maryland, USA), Embase (Reed Elsevier 
PLC, Amsterdam, The Netherlands) and Web of Science 
(Thomson Reuters, New York, USA) from their origin 
until week five October 2015. A systematic search to 
identify publications, in any language, was applied 
using the following keywords and/or Medical Subject 
Heading (MeSH) terms; (Mitotic Arrest Deficient-Like 
1 OR MAD2 or HSMAD2 or MAD2-Like Protein 1 OR 
Mitotic Arrest Deficient 2-Like Protein 1 OR Mitotic 
Spindle Assembly Checkpoint Protein MAD2A) AND 
(carcinoma(s) OR cancer(s) OR neoplasm(s) OR tumo (u) 
r(s) OR adenocarcinoma(s)).
Study selection
Inclusion criteria for studies were defined using the 
PICO model (population, intervention, control/comparison 
and outcome). The population included patients with any 
type of cancer. In order to be included in this systematic 
review, these studies needed to include the intervention 
which was an IHC method for the assessment of MAD2 
expression. Studies must also have reported a comparison 
between high/positive and low/negative MAD2 levels in 
cancerous tissue. The outcome of the study must have 
reported either the proportion of tissue samples exhibiting 
MAD2 expression (or data from which this proportion 
could be calculated) and/or the statistical association 
between MAD2 and prognosis in cancer patients. 
Conference abstracts and poster presentations were 
excluded. Only human studies and literature available in 
the English language were included. Where publications 
reported on a sample source that was entirely overlapping 
and reported on the same outcomes, only the largest/most 
recent set of results was retained. 
The principal reviewer (T. Byrne) screened all titles 
and abstracts, and two other reviewers (F. Furlong and 
J. Cooper) independently screened half of the titles and 
abstracts each. In cases where an abstract was unavailable 
or the article’s significance was unclear, the full article was 
acquired for further examination. Those identified by any 
of the two reviewers for possible inclusion were brought 
forward for full text review.
Data extraction
From the full text of identified articles, where 
available, the following data was extracted by the principal 
reviewer (T.Byrne): authors, year of publication, journal 
name, location and number of centres samples were 
obtained from, primary aim of the study, source and method 
which samples were obtained, number of participants, 
mean age and sex of participants, immunohistochemical 
methods, type of antibody, manufacturer and dilution of 
antibody, type of staining, scoring system, IHC assessment 
procedure, number of patients with positive/negative/
weak/moderate/strong MAD2 expression tumours, follow-
up time, survival, and/or recurrence results including 
reported hazard ratios (HRs), confidence intervals (CIs) 
and associated p-values. Authors from publications that 
did not have all required information were contacted to 
obtain information and summary-level data was utilised 
for meta-analysis.
Statistical analysis
Meta-analyses were conducted to determine the 
association between MAD2 expression and overall 
survival and progression-free survival, where possible. 
Several of these studies did not present the results required 
for meta-analysis as high v. low comparisons of MAD2 
expression. In the first instance authors were contacted 
to request information (provided by Furlong et al, Genga 
et al, Ko et al) [20, 23, 24]. For one study, Park et al, the 
HR for low v. high comparison was inverted in order to 
achieve comparability with studies where the HR for high 
v. low comparison was provided [25]. For other studies, 
the HR and 95% CI were derived by applying Parmar’s 
methods [26] when the number of observed deaths in 
the high and low comparison groups had been presented 
together with the log-rank p-value for the associated 
Kaplan Meier curve (conducted for Li et al, Zhang et 
al, Nakano et al – serous and mucinous ovarian cancer 
studies, Suraokar et al, Kim, Choi, Yu, Gladhaug et al and 
Genga et al studies) [21, 23, 27–34]. Adjusted/unadjusted 
HRs and 95% CI (with the maximally adjusted rates used 
where possible) were combined and weighted to provide 
pooled estimates. A random effects model was utilised in 
order to account for the anticipated heterogeneity between 
studies. Subgroup analysis was possible by cancer type 
for ovarian cancer studies, where at least three studies had 
been published, but not for other cancer types. The extent 
of heterogeneity in the pooled estimates was calculated 
using the χ2 test and I2 statistic. The I2 statistic estimates 
the degree of variation between findings that is a result of 
heterogeneity rather than chance [35]. An I2 statistic above 
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25%, 50% or 75% was decided to denote mild, moderate 
and high heterogeneity respectively [36]. In order to 
evaluate publication bias, funnel plots were constructed 
according to the Begg and Egger methods, by plotting 
relative risks to their corresponding standard errors 
[37, 38]. In addition, sensitivity analysis was conducted 
to determine excessive influences of studies by removing 
each study individually and assessing the effect on pooled 
estimates and the heterogeneity I2 statistic [39]. Statistical 
analysis was conducted utilising Stata version 11.2 
software (Stata Corporation, College Station, TX, USA).
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